Whole cohort (n=5248) | Non-diabetes group (n=4665) | Diabetes group (n=583) | |||||||
OR (95% CI), p value | OR (95% CI), p value | OR (95% CI), p value | |||||||
Model 1 | Model 2 | Model 3 | Model 1 | Model 2 | Model 3 | Model 1 | Model 2 | Model 3 | |
PAD | 1.16 (1.09 to 1.25), <0.001 | 1.15 (1.08 to 1.24), <0.000 | 1.12 (1.04 to 1.21), 0.004 | 1.14 (1.06 to 1.23), <0.001 | 1.14 (1.06 to 1.23), 0.001 | 1.10 (1.01 to 1.21), 0.029 | 1.23 (1.05 to 1.43), 0.011 | 1.22 (1.04 to 1.43), 0.013 | 1.19 (1.03 to 1.41), 0.046 |
Nephropathy | 1.15 (1.08 to 1.22), <0.001 | 1.12 (1.05 to 1.19), 0.001 | 1.13 (1.05 to 1.21), 0.001 | 1.13 (1.05 to 1.21), 0.001 | 1.10 (1.02 to 1.18), 0.014 | 1.12 (1.04 to 1.22), 0.004 | 1.17 (1.01 to 1.35), 0.040 | 1.17 (1.01 to 1.36), 0.037 | 1.13 (0.97 to 1.31), 0.120 |
Albuminuria | 1.16 (1.08 to 1.23), <0.001 | 1.14 (1.07 to 1.22), <0.001 | 1.16 (1.08 to 1.24), <0.001 | 1.14 (1.06 to 1.22), 0.001 | 1.12 (1.04 to 1.20), 0.003 | 1.15 (1.05 to 1.24), 0.001 | 1.19 (1.02 to 1.38), 0.023 | 1.20 (1.03 to 1.39), 0.021 | 1.16 (0.99 to 1.36), 0.066 |
Low eGFR | 1.10 (1.00 to 1.21), 0.049 | 1.03 (0.93 to 1.15), 0.548 | 1.03 (0.91 to 1.17), 0.627 | 1.12 (1.02 to 1.23), 0.024 | 1.05 (0.94 to 1.17), 0.398 | 1.07 (0.94 to 1.21), 0.316 | 0.90 (0.58 to 1.39), 0.621 | 0.94 (0.63 to 1.43), 0.788 | 0.84 (0.47 to 1.49), 0.551 |
Whole group analyses: model 1 was unadjusted; model 2 adjusted for age and sex; model 3 adjusted additionally for site of residence, smoking, BMI, systolic blood pressure, diabetes and LDL-cholesterol.
Subgroup (diabetes and non-diabetes) analyses: model 1 was unadjusted; model 2 adjusted for age and sex; model 3 adjusted additionally for site of residence, smoking, BMI, systolic blood pressure, and LDL-cholesterol.
BMI, body mass index; CRP, C reactive protein; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; PAD, peripheral artery disease.